• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » J&J touts NEJM publication of 5-year Type II diabetes bariatric surgery study

J&J touts NEJM publication of 5-year Type II diabetes bariatric surgery study

February 16, 2017 By Fink Densford

EthiconJohnson & Johnson (NYSE:JNJ) said today that 5-year results from the Ethicon-funded Stampede trial exploring the benefits of bariatric surgery and intensive medical therapy for diabetes patients were published in the New England Journal of Medicine.

The trial aimed to explore the use of bariatric surgery and medical therapy for obese Type II diabetes patients with a BMI of greater than or equal to 27, according to Johnson & Johnson.

At 5 years, patients who underwent bariatric surgery reported sustained gylcemic control improvements and less diabetes medications, according to the study.

“The landmark Stampede study, along with other studies supported by Ethicon, provide the high level evidence that inform and influence treatment options. The American Diabetes Association’s newly updated Standards of Care in Diabetes is the most recent example of how research matters, and how studies like Stampede are impacting the standard of care,” J&J therapeutic area lead for metabolics Dr. Elliott Fegelman said in a prepared statement.

J&J’s Ethicon said it will continue to explore the effectiveness of bariatric and metabolic surgery with the ARMMS study, which when combined with the Stampede and 3 other trials will provide data on the impact of such surgeries for up to 10 years.

“With the new guidelines from ADA and other major diabetes organizations, type 2 diabetes officially becomes an operable disease and bariatric/metabolic surgery a standard-of-care treatment. This is truly a historic development. It is crucial that primary care physicians, policy makers and the public at large be made aware of the new guidelines so that appropriate surgical candidates can have access to a clinically proven and cost-effective form of diabetes treatment,” Dr. Francesco Rubino of King’s College London said in a press release.

J&J’s Ethicon subsidiary said last month it won FDA 510(k) clearance for its Echelon Flex 45mm endocutter with proprietary gripping surface technology.

The clearance follows an earlier pass by the federal agency for Ethicon’s Echelon Flex 60mm powered plus stapler. With the new clearance, Echelon’s Flex GST system offers both 45mm and 60mm endocutters with exclusive reloads.

Filed Under: Clinical Trials, Diabetes Tagged With: Ethicon, Johnson and Johnson

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy